Case Report

Severe Thrombocytopenic Purpura in a Child with Brucellosis: Case Presentation and Review of the Literature

Alexandros Makis, Aikaterini Perogiannaki, and Nikolaos Chaliasos
Child Health Department, Faculty of Medicine, University of Ioannina, Ioannina, Greece

Correspondence should be addressed to Alexandros Makis; amakis@cc.uoi.gr

Received 10 October 2016; Accepted 15 December 2016; Published 3 January 2017

Academic Editor: Lawrence Yamuah

Copyright © 2017 Alexandros Makis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brucellosis is still endemic and a significant public health problem in many Mediterranean countries, including Greece. It is a multisystemic disease with a broad spectrum of clinical manifestations including hematological disorders, such as anemia, pancytopenia, leucopenia, and thrombocytopenia. Thrombocytopenia is usually moderate and attributed to bone marrow suppression or hypersplenism. Rarely, autoimmune stimulation can cause severe thrombocytopenia with clinically significant hemorrhagic manifestations. We present the case of a girl with severe thrombocytopenic purpura as one of the presenting symptoms of Brucella melitensis infection. Treatment with intravenous immunoglobulin and the appropriate antimicrobial agents promptly resolved the thrombocyte counts. A review of similar published cases is also presented.

1. Introduction

Brucellosis is a zoonotic infection, which is endemic in Northwestern Greece [1] and is caused by Gram-negative bacteria that belong to the genus Brucella. Brucella melitensis is the most virulent form of the disease for humans. As far as the pediatric population is concerned, the infection is transmitted by direct contact with the contaminated animals or their fluids and by consumption of unpasteurized milk or other dairy products.

Several hematological manifestations such as anemia, leucopenia, thrombocytopenia, pancytopenia, leukocytosis, and thrombocytosis have been reported at diagnosis as well as during the course of the disease [2]. The pathophysiology of these abnormalities remains unclear but several mechanisms have been suggested including direct bone marrow infiltration, hypersplenism, hemophagocytosis, and activation of the immune system with production of autoantibodies.

Thrombocytopenia caused by Brucella is usually mild with no hemorrhagic complications and subsides after appropriate antibiotic treatment for the disease [1, 3]. Less often, immune mediated severe platelet depletion can occur at diagnosis or during the course of the disease, with significant bleeding manifestations. Isolated thrombocytopenia has been reported as the first symptom of the disease, initially misdiagnosed as primary immune thrombocytopenic purpura (ITP) [4]. The purpose of this paper is to describe the case of an immune mediated severe thrombocytopenia in a small child during the course of brucellosis and to present the relevant literature review.

2. Case Report

A 5.5-year-old girl presented with six-day fever up to 38.5°C with spikes mostly in the afternoon, accompanied by pain at the right wrist joint and right elbow joint. The girl's parents are stockbreeders and homemade dairy products had been offered to the child. Three days prior to her admission in our department, she was examined in another hospital, where no remarkable findings from the joints or other systems were noted. As shown in Table 1, laboratory tests were white blood cells $7.2 \times 10^3/L$, platelets $180 \times 10^3/L$, hemoglobin $131g/L$, erythrocyte sedimentation rate (ESR) 19 mm/h, C-reactive protein (CRP) 10 mg/L, monotest negative, alanine aminotransferase (AST) 62 U/L, positive Wright agglutination reaction (title 1/1280), and negative Rose Bengal. Based on the symptoms and the positive Wright reaction, treatment for brucellosis was initiated. Trimethoprim/sulfamethoxazole
(TMP/SMX) (10 mg/kg/day) and rifampicin (15 mg/kg/day) were administered orally.

On the third day of treatment, generalized purpuric lesions were noted accompanied with severe thrombocytopenia (platelets $3 \times 10^9/L$) and the child was referred to our hospital. On admission the child was febrile (38.8° C) and generalized petechial/purpuric rash, bruising, wet purpura on the palate, and gingival bleeding were noted, while the spleen and the liver were palpable 2 cm below the subcostal margin at the midclavicular line. Examination of the joints and the other systems did not reveal any pathological signs.

Laboratory tests showed white blood cells $7.5 \times 10^9/L$ (neutrophils 45%, lymphocytes 52%, and monocytes 3%), platelets $1 \times 10^9/L$, hemoglobin 120 g/L, ESR 15 mm/h, CRP 7 mg/L, AST 64 U/L, urea 4.1 mmol/L, creatinine 92 μmol/L, and total bilirubin 12 μmol/L. Wright agglutination reaction was positive (title 1/1280), as well as the specific IgM, IgA antibodies against Brucella melitensis. The specific IgG antibodies were negative. Blood cultures were sterile. Direct and indirect Coombs were negative. The quantification of immunoglobulins IgG, IgM, and IgA and complements C3 and C4 was within normal range. Antinuclear antibodies, anti-double stranded DNA antibodies, and rheumatoid factor were negative, while the antiplatelet antibody test was positive. Clotting time and fibrinogen were normal (Table 1).

Due to the very low platelet count and the mucous membrane hemorrhage, treatment with intravenous immunoglobulin (IVIG) (1 g/kg/day for two days) was initiated, combined with antibiotic therapy with amikacin intravenously (15 mg/kg/day for seven days) and oral rifampicin. TMP/SMX treatment was stopped due to the suspicion of drug-induced thrombocytopenia.

The patient responded with a gradual increase in the number of platelets up to $218 \times 10^9/L$ five days after treatment. At this stage, oral TMP/SMX administration was reinitiated, without any negative effect on the platelet count. On the contrary, a rise in platelet number up to $503 \times 10^9/L$ was observed. Fever resolved at the second day of treatment and no new bleeding manifestations appeared. The patient was discharged with rifampicin and TMP/SMX as maintenance therapy for a total six-week treatment. She completed the treatment without further complications and during the regular follow-up platelet counts were normal (Table 1).

### 3. Discussion

Thrombocytopenia is one of the hematological manifestations of brucellosis in children with a variable percentage of 5–40% in several studies [1–3, 5, 6]. The pathogenic pathways of Brucella-related thrombocytopenia have not been fully elucidated, with hypersplenism, hemophagocytosis, bone marrow suppression, and antiplatelet antibodies production being the most possible mechanisms. It is usually moderate without clinically significant bleeding problems. Less often, severe isolated thrombocytopenia occurs, possibly immune mediated, mimicking ITP (Table 2).

In Greece, several cases of severe thrombocytopenia have been described over the years. In 1998, Benecos et al. from our department reported a case of a boy who presented with severe thrombocytopenic purpura with petechiae, epistaxis, oral bleeding, and positive antiplatelet antibodies. He was initially treated as ITP with IVIG with good clinical and hematological response. A few days later prolonged fever occurred with persistent hepatomegaly and positive blood culture for Brucella melitensis and the child was successfully treated with streptomycin and TMP/SMX [7]. Tsirka et al. reported an 11-year-old boy with anemia, leukopenia, and severe thrombocytopenic purpura, who was treated as ITP with IVIG with an initial good response. Surprisingly, a few days later a blood culture was positive for Brucella melitensis and treatment with gentamicin, doxycycline, and rifampicin was successfully implemented [8]. Tsolia et al. presented 39 children diagnosed with brucellosis over a period of 15 years in central Greece, two of whom had severe thrombocytopenic purpura and received oral antibiotic therapy with a good outcome [3].

In Turkey brucellosis remains a major public health problem, with approximately 15000 cases per year. Pediatric patients represent 20–25% of all cases [9]. Authors from several areas of the country have reported cases of isolated severe thrombocytopenia as the presenting feature of brucellosis that responded well to appropriate antibiotic treatment combined with corticosteroids or IVIG. Fever was noticed in most cases, with positive blood culture for Brucella [10–13].

Apart from these case reports, large series of pediatric patients with brucellosis have been studied in Turkey with interesting findings regarding Brucella-related severe thrombocytopenia. Akbayram et al. reported five cases presenting with isolated thrombocytopenia out of 187 children (2.6%) diagnosed with brucellosis in one hospital in Turkey between

### Table 1: Hematological parameters and treatment at admission and during the course of the disease.

| Treatment                  | 3 days before admission | Admission | Day 5 | Day 10 | Week 6 |
|----------------------------|-------------------------|-----------|-------|--------|--------|
| WBC ($\times 10^9$/L)      | 7.2                     | 75        | 8.7   | 7.2    | 9.9    |
| Ht                         | 0.37                    | 0.33      | 0.38  | 0.37   | 0.38   |
| Hb (g/L)                   | 131                     | 120       | 126   | 121    | 129    |
| Plt ($\times 10^9$/L)      | 180                     | 1         | 218   | 503    | 315    |

TMP/SMX: trimethoprim/sulfamethoxazole; WBC: white blood cell count; Ht: hematocrit; Hb: hemoglobin; Plt: platelets.

The patient responded with a gradual increase in the number of platelets up to $218 \times 10^9/L$ five days after treatment. At this stage, oral TMP/SMX administration was reinitiated, without any negative effect on the platelet count. On the contrary, a rise in platelet number up to $503 \times 10^9/L$ was observed. Fever resolved at the second day of treatment and no new bleeding manifestations appeared. The patient was discharged with rifampicin and TMP/SMX as maintenance therapy for a total six-week treatment. She completed the treatment without further complications and during the regular follow-up platelet counts were normal (Table 1).
Table 2: Cases of children with brucellosis and severe thrombocytopenia.

| Country     | Authors                      | Year | Number of cases | Treatment                                                                 | Outcome |
|-------------|------------------------------|------|-----------------|---------------------------------------------------------------------------|---------|
| Greece      | Benecos et al.               | 1998 | 1               | IVIG, TMP/SMX, streptomycin                                               | Good    |
|             | Tsirka et al.                | 2002 | 1               | IVIG, gentamycin, doxycycline, rifampicin                                 | Good    |
|             | Tsolia et al.                | 2002 | 2               | TMP/SMX, rifampicin                                                       | Good    |
| Turkey      | Sevinc et al.                | 2000 | 1               | Corticosteroids, TMP/SMX, rifampicin, ciprofloxacin                       | Good    |
|             | Yalaz et al.                 | 2004 | 1               | Doxycycline, rifampicin                                                   | Good    |
|             | Ulug et al.                  | 2011 | 1               | TMP/SMX, rifampicin                                                       | Good    |
|             | Akbayram et al.              | 2011 | 5               | Doxycycline and rifampicin (>8 years) or TMP/SMX and rifampicin (<8 years)| Good    |
|             | Citak et al.                 | 2010 | 5               | IVIG, TMP/SMX, rifampicin                                                 | Good    |
|             | Aypak et al.                 | 2016 | 11              | Doxycycline and rifampicin (>8 years) or TMP/SMX and rifampicin (<8 years)| Good    |
|             | Karaman et al.               | 2016 | 15              | Doxycycline and rifampicin (>8 years) or TMP/SMX and rifampicin (<8 years)| Good    |
| Saudi Arabia| Benjamin and Annobil         | 1992 | 4               | Rifampicin, TMP/SMX, doxycycline, streptomycin                           | Good    |
|             | Al-Eissa and Al-Nasser       | 1993 | 5               | Rifampicin, TMP/SMX, doxycycline, streptomycin                           | Good    |
|             | Benjamin                     | 1995 | 2               | Rifampicin, TMP/SMX, doxycycline                                          | Good    |
| Lebanon     | Farah et al.                 | 2010 | 1               | IVIG, TMP/SMX, gentamycin                                                 | Good    |
| Israel      | Marom et al.                 | 2000 | 1               | Rifampicin, TMP/SMX                                                       | Good    |
| Iran        | Kamali Aghdam et al.         | 2016 | 1               | IVIG, rifampicin, TMP/SMX                                                 | Good    |

TMP/SMX: trimethoprim/sulfamethoxazole.
2004 and 2010. All patients had a complete recovery and their platelet counts returned to normal after the administration of a combination of doxycycline and rifampicin or TMP/SMX and rifampicin [14]. During the same period in another hospital, Citak et al. retrospectively assessed the records of 146 children with brucellosis. Among them, 5 (3.4%) presented with immune thrombocytopenia, which was severe and manifested with a variety of symptoms and positive blood cultures for the bacteria. Apart from the appropriate antibiotic treatment, IVIG was administered with excellent response [6]. Aypak et al. evaluated the hematological findings in 69 children who were diagnosed with brucellosis over a one-year period [2010-2011] and 15.9% of them presented with thrombocytopenia restored after antibiotic treatment without the need of corticosteroids or IVIG [5].

In countries of the Middle East where brucellosis is a significant health problem, isolated severe thrombocytopenia has been reported as a presenting symptom in several cases. In a series of 115 children with brucellosis in Saudi Arabia, four of them had severe thrombocytopenia and proper oral antibiotic therapy led to quick recovery [15]. In another study, clinically significant thrombocytopenia was found in 5 children from a population of 110 children with brucellosis and it was successfully treated with antibiotics [16]. Benjamin described two cases of children with fever, thrombocytopenic purpura, and mucosal bleeding which resolved promptly with the initiation of antimicrobial therapy. Thrombocytopenia was attributed to peripheral destruction since large platelets in the peripheral blood and proliferation of megakaryocytes in the bone marrow were identified: an image resembling ITP [17]. In 2010, Farah et al. in Lebanon reported a case of severe thrombocytopenic purpura as the sole manifestation of 622 children with brucellosis over a 6-year period. Isolated severe thrombocytopenia was found in 16 patients (2.5%), which resolved with antibiotics or IVIG [5].

As far as our case is concerned, we faced some difficulties which raised certain concerns. The patient was admitted with extremely low platelet count and bleeding lesions of the mucous membranes. Consequently, the risk of internal or intracranial bleeding and the need for immediate intervention were urgent. Therefore, IVIG and intravenous treatment with aminoglycoside were administered, which led to a rapid and significant increase in platelet count.

Another discussion topic is the possibility of the involvement of the drugs already administered to the patient in the induction of thrombocytopenia. Rifampicin is a drug that could cause thrombocytopenia, but it is usually mild and clinically insignificant, whereas TMP/SMX can occasionally cause severe drop in platelet count with significant bleeding. Therefore, we decided to stop TMP/SMX treatment. Given that the patient had to continue double antimicrobial treatment beyond the acute phase for a total of six weeks, it was decided to continue the use of rifampicin. To exclude possible drug-induced thrombocytopenia from TMP/SMX, the drug was reintroduced after the stabilization of the patient’s condition and this had no effect on the platelet count.

In conclusion, in regions where brucellosis is endemic, it should be included in the differential diagnosis in cases of ITP. There should be an individualized approach to each patient but in any case the administration of IVIG or corticosteroids is of great significance, while the final and main resolution occurs with appropriate antimicrobial therapy.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] E. Galanakis, K. L. Bourantas, S. Leveidiotou, and P. D. Lapatsanis, “Childhood brucellosis in north-western Greece: a retrospective analysis,” European Journal of Pediatrics, vol. 155, no. 1, pp. 1–6, 1996.
[2] A. Aypak, C. Aypak, and Y. Bayram, “Hematological findings in children with brucellosis,” Pediatrics International, vol. 57, no. 6, pp. 1108–1111, 2016.
[3] M. Tsolia, S. Drakonaki, A. Messaritaki et al., “Clinical features, complications and treatment outcome of childhood brucellosis in central Greece,” Journal of Infection, vol. 44, no. 4, pp. 257–262, 2002.
[4] M. Yilmaz, O. Tiryaki, M. Namiduru et al., “Brucellosis-induced immune thrombocytopenia mimicking ITP: a report of seven cases,” International Journal of Laboratory Hematology, vol. 29, no. 6, pp. 442–445, 2007.
[5] K. Karaman, S. Akbayram, G. İ. Bayhan et al., “Hematologic findings in children with brucellosis: experiences of 622 patients in eastern Turkey,” Journal of Pediatric Hematology/Oncology, vol. 38, no. 6, pp. 463–466, 2016.
[6] E. C. Citak, F. E. Citak, B. Tanyeri, and D. Arman, “Hematologic manifestations of brucellosis in children: 5 years experience of an anatolian center,” Journal of Pediatric Hematology/Oncology, vol. 32, no. 2, pp. 137–140, 2010.
[7] P. Benecos, T. Spingou, E. Galanakis, and P. D. Lapatsanis, “Thrombocytopenic purpura secondary to brucellosis,” European Journal of Pediatrics, vol. 157, no. 8, article no. 698, 1998.
[8] A. Tsirka, I. Markesinis, V. Getsi, and S. Chaloulou, “Severe thrombocytopenic purpura due to brucellosis,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 7, pp. 535–536, 2002.

[9] Z. Yumuk and D. O’Callaghan, “Brucellosis in Turkey—an overview,” International Journal of Infectious Diseases, vol. 16, no. 4, pp. e228–e235, 2012.

[10] A. Sevínç, N. O. Kutlu, I. Kuku, U. Ozgen, I. Aydogdu, and H. Soylu, “Severe epistaxis in brucellosis-induced isolated thrombocytopenia: a report of two cases,” Clinical and Laboratory Haematology, vol. 22, no. 6, pp. 373–375, 2000.

[11] M. Yalaz, M. T. Arslan, and Z. Kurugöl, “Thrombocytopenic purpura as only manifestation of brucellosis in a child,” Turkish Journal of Pediatrics, vol. 46, no. 3, pp. 265–267, 2004.

[12] M. Ulug, F. Yapıcı, and N. Can-Ulug, “Unusual clinical presentations of brucellosis in childhood,” Brazilian Journal of Infectious Diseases, vol. 15, no. 4, pp. 406–407, 2011.

[13] R. Sac, N. Yarali, B. Tavıl, M. F. Azık, A. Kara, and B. Tunc, “Severe persistent thrombocytopenia as a sole manifestation of brucellosis,” Indian Journal of Pediatrics, vol. 80, no. 1, pp. 85–86, 2013.

[14] S. Akbayram, M. Dogan, C. Akgun, E. Peker, M. Parlak, and A. F. Oner, “An analysis of children with brucellosis associated with isolated thrombocytopenia,” Clinical and Applied Thrombosis/Hemostasis, vol. 17, no. 6, pp. E36–E38, 2011.

[15] B. Benjamin and S. H. Annobil, “Childhood brucellosis in Southwestern Saudi Arabia: a 5-year experience,” Journal of Tropical Pediatrics, vol. 38, no. 4, pp. 167–172, 1992.

[16] Y. Al-Eissa and M. Al-Nasser, “Haematological manifestations of childhood brucellosis,” Infection, vol. 21, no. 1, pp. 23–26, 1993.

[17] B. Benjamin, “Acute thrombocytopenic purpura in childhood brucellosis,” Annals of Tropical Paediatrics, vol. 15, no. 3, pp. 189–192, 1995.

[18] R. A. Farah, P. Hage, A. Al Rifai, and C. Afif, “Immune thrombocytopenic purpura associated with brucellosis. Case report and review of the literature,” Journal Medical Libanais, vol. 58, no. 4, pp. 241–243, 2010.

[19] M. Kamali Aghdam, K. Davari, and K. Eftekhari, “Recurrent epistaxis and bleeding as the initial manifestation of brucellosis,” Acta Medica Iranica, vol. 54, no. 3, pp. 218–219, 2016.

[20] R. Marom, D. Miron, H. Gabriel, and Y. Horowitz, “Thrombocytopenic purpura as sole manifestation of brucellosis in children,” Harefiah, vol. 139, no. 7-8, pp. 278–326, 2000.